BioSpace News Archive

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, is kicking off 2024 with the GenScript Biotech Global Forum 2024, concurrent with the 42nd Annual J.P. Morgan Healthcare Conference.

Biogen Inc. and Sage Therapeutics, Inc. announced ZURZUVAE™ 50 mg CIV is now available by prescription for the treatment of postpartum depression for adults in the United States, with product already at specialty pharmacies and delivered to patients.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”) announces selection of contract research organization (“CRO”) George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).

Kraig Biocraft Laboratories, Inc. announces the early start to the production season with the successful manufacture and delivery of the most recent batch of recombinant spider silk.

Bio-Path Holdings, Inc. announced completion of the first dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients including venetoclax-resistant patients.

Bio-Techne Corporation announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2023.

Terray Therapeutics today announced a multi-target collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to discover and develop small molecule therapeutics in certain disease areas.

TriSalus Life Sciences® Inc. is pleased to announce that the Centers for Medicare & Medicaid Services has created a New Technology Healthcare Common Procedure Coding System code for procedures involving the TriNav® Infusion System.

Glaukos Corporation (NYSE: GKOS) announced today the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).